|
|
|
| Effect of Peramivir in the treatment of children with influenza and pneumonia |
| AN Zhihua1 ZHANG Guying1 DONG Lei1 JIA Chenhong1 FU Haiyan2 |
1.Department of Pharmacy, Hebei Children′s Hospital, Hebei Province, Shijiazhuang 050031, China;
2.Department of Gastroenterology, Hebei Children′s Hospital, Hebei Province, Shijiazhuang 050031, China |
|
|
|
Abstract Objective To investigate the clinical effects and adverse reactions of Peramivir Sodium Chloride Injection in the treatment of children with influenza and pneumonia. Methods A total of 100 children hospitalized in Hebei Children′s Hospital from November 2018 to March 2019 were collected and divided into the control group and the observation group according to the random number table method, with 50 cases in each group. The control group was treated with Oseltamivir Phosphate Granules, and the observation group was treated with Peramivir Sodium Chloride Injection. The clinical efficacy, total effective rate, viral antigen negative conversion rate, adverse reactions and blood routine changes after 5 days of the two groups during the treatment were compared. Results The duration of fever, cough, lung rales and hospital stay in the observation group were significantly shorter than those in the control group, with statistically significant differences (all P ＜ 0.05). However, there was no statistically significant difference in the duration of pharyngeal congestion between the two groups (P ＞ 0.05). The total effective rate and viral antigen negative conversion rate of the observation group were higher than those of the control group, with statistically significant differences (all P ＜ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). There was no statistically significant difference between the two groups in blood routine indexes before treatment (P ＞ 0.05). After 5 days of treatment, the percentage of neutrophils in the two groups was significantly higher than before treatment, and the observation group was higher than the control group, while the C-reactive protein was significantly lower than before treatment, and the observation group was lower than the control group, with statistically significant differences (all P ＜ 0.05). Platelets were higher in the control group 5 days after treatment than before treatment, and the difference was statistically significant (P ＜ 0.05). However, there was no statistically significant difference in white blood cells, red blood cells, the percentage of lymphocytes and platelets between the two groups after 5 days of treatment (P ＞ 0.05). Conclusion In the treatment of children with influenza and pneumonia, the clinical effect of Peramivir is better than Oseltamivir, can improve the total effective rate, shorten the hospital stay, and the virus antigen conversion rate is higher, blood routine to normal value is more obvious, the effect is fast, worthy of clinical promotion.
|
|
|
|
|
|
[1] 刘珺，钱素云.儿童重症流感的诊治要点[J].北京医学，2019，11（41）：1200-1202.
[2] Naumov P，Yasuda N，Rabeh WM，et al. The elusive crystal structure ofthe neuraminidase inhibitor Tamiflu（ehamivir phosphate）：molecular details of action [J]. Chem Commun（Camb），2013，49（19）：1948-1950
[3] Li G，Yilmaz M，Kojicic M，et al. Outcome of critically ill patients with influenza virus infection [J]. J Clin Virol，2009，46（3）：275-278.
[4] 王媚，皮光环.磷酸奥司他韦治疗小儿甲型H1N1流感的效果及安全性[J].临床医学，2019，4（27）：84-85.
[5] 马宇廷，邹映雪.儿童流感病毒感染的临床特征研究进展[J].医学综述，2017，23（6）：1179-1182.
[6] 国家卫生和计划生育委员会，国家中医药管理局.流行性感冒诊疗方案（2018年版）[J].中国感染控制杂志，2018， 17（2）：181-184.
[7] 苏伟，张复春.甲型流感研究进展[J].新发传染病电子杂志，2018，3（3）：182-187.
[8] 李晓光，胥婕，李璐，等.帕拉米韦氯化钠注射液治疗无并发症的急性单纯性流行性感冒的临床疗效及安全性评价[J].中国临床药理学杂志，2016，32（5）：387-389.
[9] 张菲菲，杨淑惠，张旭，等.帕拉米韦治疗流感病毒感染患儿的效果观察及对机体免疫、炎性指标的影响[J].中国医院药学杂志，2019，32（8）：21-27.
[10] 刘秀菊，董维冲，郭鹏辉，等.帕拉米韦治疗流感的临床研究进展[J].中国新药杂志，2017，26（8）：899-903.
[11] 李晓光，胥婕，李璐，等.帕拉米韦治疗流行性感冒的疗效及安全性分析[J].临床药物治疗杂志，2019，17（9）：24-27.
[12] 王周菊，林菁.帕拉米韦氯化钠注射液治疗小儿流行性感冒并发肺炎的临床效果[J].中国当代医药，2019，26（10）：135-137.
[13] 郑继岿.帕拉米韦氯化钠注射液治疗小儿流行性感冒并发肺炎的临床效果[J].中国实用儿科杂志，2018，33（6）：409-413.
[14] Kondo K，Suzuki K，Washio M，et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly-Selection of controls in a casecontrol study [J]. Vaccine，2017，35（36）：4806-4810.
[15] 张富义，高李华.帕拉米韦氯化钠注射液治疗儿童流行性感冒疗效观察[J].中国现代医生，2018，56（30）：57-60.
[16] 李娟.儿童流感应用帕拉米韦对临床症状、免疫应答和炎性反应的影响[J].中国临床医生杂志，2019，47（8）：983-985.
[17] 武辉娟.儿童甲型流感发病早期白细胞及C反应蛋白的特点[J].北京医学，2019，41（7）：613-614.
[18] 王彦晖.王彦晖治疗流行性感冒临证经验总结[J].中华中医药杂志，2019，34（6）：2499-2502.
[19] 陈圣洁，戴兰芬，李丹丹，等.帕拉米韦与奥司他韦治疗儿童流感病毒肺炎的成本-效果分析[J].中国医药，2019，14（2）：215-218.
[20] Robson C，Baskar SR，Booy R，et al. Influenza：overview on prevention and therapy [J]. Aust Prescr，2019，42（2）：51-55.
[21] 刘姗娟.儿科奥司他韦超说明书用药调查研究[J].中国医药科学，2019，9（15）：62-64，211.
[22] 王丽燕，刘田田.帕拉米韦氯化钠注射液治疗儿童流感病毒感染的临床疗效和安全性对比[J].中国医院药学杂志，2018，38（12）：1307-1310. |
|
|
|
